133 results on '"Tsukita, Yoko"'
Search Results
2. Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)
3. Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial
4. Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047)
5. Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)
6. Antibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment
7. Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study
8. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non–small cell lung cancer: A multicenter retrospective cohort study
9. Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting
10. Decreased expression of airway epithelial Axl is associated with eosinophilic inflammation in severe asthma
11. Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
12. Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC
13. IgA Vasculitis during Atezolizumab Treatment
14. Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study
15. Multi-institutional study of osimertinib dose-optimization in non-small cell lung cancer patients with EGFR activating mutation aged 70 years or older ('MONEY' trial).
16. Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas
17. Durvalumab after chemoradiotherapy in non‐small cell lung cancer with EGFR mutation: A real‐world study (HOT2101)
18. Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer.
19. MO3-6 The elderly subgroup analysis in real world survey (CRIMSON) of concurrent chemoradiotherapy in locally advanced NSCLC
20. MO57-4 Association of Glasgow prognostic score with efficacy and safety of first-line osimertinib in EGFR mutated NSCLC (OSI-FACT exploratory analysis)
21. Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426]
22. Longitudinal analyses and predictive factors of radiation-induced lung toxicity-related parameters after stereotactic radiotherapy for lung cancer
23. Antibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment
24. Clinical features of COVID-19 patients with rebound phenomenon after corticosteroid therapy
25. Stereotactic Radiosurgery for Lung Cancer with a Risk-Adapted Strategy Using the Volumetric Modulated Arc Therapy Technique: A Single Arm Phase II Study
26. MO4-4 Safety of immune checkpoint blockade in lung cancer and pre-existing autoimmune diseases: NEJ047 multi-center study
27. First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study
28. Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)
29. Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study
30. Aspiration pneumonia induces muscle atrophy in the respiratory, skeletal, and swallowing systems
31. A Case of Small Cell Lung Cancer with Cancer-Associated Retinopathy (CAR) Accompanied by Circulating Anti-CRMP5/CV2 Antibodies: OS023
32. Immunotherapy-related hepatitis and thrombocytopaenia induced by the very low dose of only 90 mg of atezolizumab
33. A case of localized tracheobronchial relapsing polychondritis with positive matrilin-1 staining
34. Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203
35. Additional file 1: of Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas
36. Additional file3: of Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas
37. Phase II study of S-1 in patients (pts) with previously treated Invasive thymoma (IT) and thymic carcinoma (TC): North Japan Lung Cancer Study Group Trial 1203.
38. Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth factor receptor mutations
39. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas
40. Beneficial effects of sunitinib on tumor microenvironment and immunotherapy targeting death receptor5
41. Effects of a combination of antiangiogenic and antilymphangiogenic therapies on a death receptor-5 mediated antitumor immunotherapy in mice.
42. Second-line chemotherapy efficacy in patients with previously treated advanced thymic carcinoma: A retrospective analysis of 192 patients from NEJ023 Study.
43. EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method
44. A Case of Infection of Chlamydophila Pneumoniae with ARDS
45. First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057).
46. Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma
47. Preferential Fat Intake of Pups Nursed by Dams Fed Low Fat Diet during Pregnancy and Lactation Is Higher than That of Pups Nursed by Dams Fed Control Diet and High Fat Diet
48. Drug-related pneumonitis induced by osimertinib as first-line treatment for EGFR-positive non-small cell lung cancer: a real-world setting
49. Beneficial effects of sunitinib on tumor microenvironment and immunotherapy targeting death receptor5.
50. Chemoimmunotherapy in Older Adults With Non-Small Cell Lung Cancer-Reply.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.